ClinicalTrials.gg
CompletedNCT02279407EFFECTIIUpdated Mar 17, 2017Results posted

A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients

A Phase 2 interventional study of placebo and Omega-3 carboxylic acids in T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin), sponsored by AstraZeneca. Completed at 5 sites in Sweden. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-03-17.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
223
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing dapagliflozin in Non-alcoholic Fatty Liver Disease — none open to participants now, 2 under way, none of them phase 3. dapagliflozin · Non-alcoholic Fatty Liver Disease.

Enrollment
Largest of 10
223 · median 104
Started
2015
the only one that year
Phase 2
2 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
1 of 10
AstraZeneca

Among the 10 studies testing dapagliflozin in Non-alcoholic Fatty Liver Disease, this one has the largest enrollment, is the only one that started in 2015, is one of 2 in phase 2, and was the 1st registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 10 studies testing dapagliflozin in Non-alcoholic Fatty Liver Disease is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Where they have run

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing dapagliflozin in Non-alcoholic Fatty Liver Disease as a file.
02

Study summary

This study is a double-blind randomized, placebo-controlled, parallel-group, 12 week study performed in up to 5 centres in Sweden to assess the effect of Omega-3 carboxylic acids and dapagliflozin on liver fat in patients with Type 2 diabetes with fatty liver (>5.5% as measured with magnetic resonance imaging (MRI))

03

Conditions studied

  • T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)

Keywords

  • omega-3 carboxylic acid
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Provision of prior to any study specific procedures; Men or women ≥40 years and ≤75 years with suitable veins for cannulation or repeated venepuncture; Have liver fat content as assessed by MRI >5.5%; Diagnosis of Type 2 diabetes since at least 6 months in accordance with WHO criteria.

Exclusion Criteria: Any condition when MRI is such as, but not limited to, having a pacemaker or claustrophobia; Diagnosis or signs of Type 1 diabetes (e.g. history of positive islet antibodies); \<60 mL/min at screening (Cockcroft-Gault formula).

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
223 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Drug: placebo

  • Experimental
    Omega-3 carboxylic acids 4g / day

    Drug: Omega-3 carboxylic acids

  • Experimental
    Dapagliflozin, 10mg / day

    Drug: Dapagliflozin

  • Experimental
    Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day

    Drug: Omega-3 carboxylic acids · Drug: Dapagliflozin

Interventions

  • Drugplacebo

    Placebo matching to Omega-3 carboxylic acids (olive oil)

  • 4 g administered as 4 x 1 g capsules

  • 10 mg administered as 10 mg tablet

  • DrugPlacebo

    Placebo matching to dapagliflozin 10 mg

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in % Liver Fat as Assessed by MRI (Comparison Versus Placebo)

    To evaluate the efficacy of the combination therapy (Epanova + Dapagliflozin) when compared to placebo with respect to reduction in liver fat content (%) at the end of 12 weeks of double-blinded treatment. Treatment effect in liver fat reduction (%) was assessed using a mixed linear model with the change from baseline on logarithmic scale as response variable and the logarithm of the baseline value as covariate, treatment as fixed effect, and center as random effect. The treatment effect was then back-transformed to original scale as Geometric mean ratio and presented as percentage change from baseline.

    Time frame: 12 weeks

Secondary outcomes

  1. Change From Baseline to Week 12 in % Liver Fat (Comparison Between Active Treatment Groups)

    To evaluate the relative efficacy of the combination of Epanova and dapagliflozin versus Epanova alone and dapagliflozin alone with respect to reduction in % liver fat at the end of 12 weeks of double-blind treatment. Treatment effect in liver fat reduction (%) was assessed using a mixed linear model with the change from baseline on logarithmic scale as response variable and the logarithm of the baseline value as covariate, treatment as fixed effect, and center as random effect. The treatment effect was then back-transformed to original scale as Geometric mean ratio and presented as percentage change from baseline.

    Time frame: 12 weeks

07

Results

Posted Jan 27, 2017

Participant flow

This study was conducted in 5 centers in Sweden between 20 January 2015 and 11 December 2015.

Participant flow — Overall Study
MilestoneEpanova + DapagliflozinDapagliflozinEpanovaPlacebo
Started22212021
Completed20201520
Not completed2151
Withdrew: Couldn't swallow ip; noncompliance0020
Withdrew: Withdrawal by subject1011
Withdrew: Adverse event1120

Outcome measures

PrimaryChange From Baseline to Week 12 in % Liver Fat as Assessed by MRI (Comparison Versus Placebo)

To evaluate the efficacy of the combination therapy (Epanova + Dapagliflozin) when compared to placebo with respect to reduction in liver fat content (%) at the end of 12 weeks of double-blinded treatment. Treatment effect in liver fat reduction (%) was assessed using a mixed linear model with the change from baseline on logarithmic scale as response variable and the logarithm of the baseline value as covariate, treatment as fixed effect, and center as random effect. The treatment effect was then back-transformed to original scale as Geometric mean ratio and presented as percentage change from baseline.

Time frame:
12 weeks
Reported as:
Geometric mean · ratio of % liver fat
Change From Baseline to Week 12 in % Liver Fat as Assessed by MRI (Comparison Versus Placebo)
ratio of % liver fatEpanova + DapagliflozinPlacebo
Change From Baseline to Week 12 in % Liver Fat as Assessed by MRI (Comparison Versus Placebo)0.79 (0.69 to 0.90)0.97 (0.90 to 1.04)
Statistical analysis
  • Epanova + Dapagliflozin vs Placebo · Mixed Models Analysis · p = 0.046 (Hypotheses tested using Dunnett's multiple testing procedure with a family-wise error rate of 5%, adjusting for 3 pairwise comparisons versus a single control (placebo).) · Geometric mean ratio for difference: 0.83 · 95% CI 0.70 to 1.00
SecondaryChange From Baseline to Week 12 in % Liver Fat (Comparison Between Active Treatment Groups)

To evaluate the relative efficacy of the combination of Epanova and dapagliflozin versus Epanova alone and dapagliflozin alone with respect to reduction in % liver fat at the end of 12 weeks of double-blind treatment. Treatment effect in liver fat reduction (%) was assessed using a mixed linear model with the change from baseline on logarithmic scale as response variable and the logarithm of the baseline value as covariate, treatment as fixed effect, and center as random effect. The treatment effect was then back-transformed to original scale as Geometric mean ratio and presented as percentage change from baseline.

Time frame:
12 weeks
Reported as:
Geometric mean · ratio of % liver fat
Change From Baseline to Week 12 in % Liver Fat (Comparison Between Active Treatment Groups)
ratio of % liver fatEpanova + DapagliflozinDapagliflozinEpanova
Change From Baseline to Week 12 in % Liver Fat (Comparison Between Active Treatment Groups)0.79 (0.69 to 0.90)0.87 (0.77 to 0.99)0.85 (0.78 to 0.92)
Statistical analysis
  • Epanova + Dapagliflozin vs Dapagliflozin · Mixed Models Analysis · p = 0.502 (Conditional upon rejection of at least 1 of the 3 hypotheses for the primary analysis, secondary hypotheses are tested using Tukey's multiple testing procedure with a family-wise error rate of 5%, adjusting for 3 pairwise comparisons.) · Geometric mean ratio for difference: 0.91 · 95% CI 0.75 to 1.11
  • Epanova + Dapagliflozin vs Epanova · Mixed Models Analysis · p = 0.562 (Conditional upon rejection of at least 1 of the hypotheses for the primary analysis, secondary hypotheses are tested using Tukey's multiple testing procedure with a family-wise error rate of 5%, adjusting for 3 pairwise comparisons.) · Geometric mean ratio for difference: 0.91 · 95% CI 0.73 to 1.13

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epanova + Dapagliflozin—0/22 (0%)14/22 (63.6%)
Epanova—0/20 (0%)12/20 (60%)
Dapagliflozin—1/21 (4.8%)8/21 (38.1%)
Placebo—1/21 (4.8%)7/21 (33.3%)
Most frequent serious events
Most frequent serious events
EventEpanova + DapagliflozinEpanovaDapagliflozinPlacebo
SepsisInfections and infestations0/220/200/211/21
HydronephrosisRenal and urinary disorders0/220/201/210/21
Most frequent other events
Most frequent other events
EventEpanova + DapagliflozinEpanovaDapagliflozinPlacebo
DiarrhoeaGastrointestinal disorders11/227/201/210/21
DizzinessNervous system disorders2/221/205/211/21
NauseaGastrointestinal disorders2/223/200/212/21
Abdominal pain upperGastrointestinal disorders3/222/200/210/21
NasopharyngitisInfections and infestations2/222/201/211/21
ConstipationGastrointestinal disorders0/221/202/211/21
HeadacheNervous system disorders1/220/200/212/21
PollakiuriaRenal and urinary disorders2/221/202/211/21

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Epanova + DapagliflozinEpanovaDapagliflozinPlaceboTotal
Mean65.0 ± 5.4266.2 ± 5.9465.0 ± 6.5465.6 ± 6.1065.5 ± 5.92
Age, Customized
Age, Customized(Participants)Epanova + DapagliflozinEpanovaDapagliflozinPlaceboTotal
<5000101
>=50 - <65966627
>=651314141556
Sex: Female, Male
Sex: Female, Male(Participants)Epanova + DapagliflozinEpanovaDapagliflozinPlaceboTotal
Female795425
Male1511161759
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Epanova + DapagliflozinEpanovaDapagliflozinPlaceboTotal
Black Or African American10102
White2120202182
08

Study locations

5 sites
  • Research Site
    Göteborg, Sweden
  • Research Site
    Linkoping, Sweden
  • Research Site
    Stockholm, Sweden
  • Research Site
    Uppsala, Sweden
  • Research Site
    Örebro, Sweden
09

References and documents

Publications

  • Eriksson JW, Lundkvist P, Jansson PA, Johansson L, Kvarnstrom M, Moris L, Miliotis T, Forsberg GB, Riserus U, Lind L, Oscarsson J. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018 Sep;61(9):1923-1934. doi: 10.1007/s00125-018-4675-2. Epub 2018 Jul 3. PubMed 29971527 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2014
First posted
Oct 31, 2014
Start
Jan 2015
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
Jan 27, 2017
Last update
Mar 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02279407
Lead sponsor
AstraZeneca
Collaborators
Uppsala Clinical Research, Uppsala, Sweden
Responsible party
Sponsor
First posted
Oct 31, 2014
Start date
Jan 2015
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Jan 27, 2017
Last update
Mar 17, 2017

Study contacts

Jan Eriksson, MD
principal investigator · Uppsala University Hospital, Uppsala, SE

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Omega-3 carboxylic acid · Dapagliflozin

Start the discussion